Chemours (CC) Stock Price Down 0.4%

Shares of Chemours Co (NYSE:CC) traded down 0.4% during mid-day trading on Tuesday . The stock traded as low as $25.06 and last traded at $25.22. 86,393 shares changed hands during trading, a decline of 95% from the average session volume of 1,888,504 shares. The stock had previously closed at $25.32.

Several analysts have issued reports on the company. Royal Bank of Canada cut their price target on Chemours to $43.00 and set an “outperform” rating for the company in a report on Monday, May 6th. JPMorgan Chase & Co. lowered Chemours from an “overweight” rating to a “neutral” rating and cut their price target for the company from $40.00 to $34.00 in a report on Monday, May 6th. ValuEngine lowered Chemours from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 1st. SunTrust Banks raised Chemours from a “hold” rating to a “buy” rating and boosted their price target for the company from $40.00 to $52.00 in a report on Monday, April 15th. Finally, Zacks Investment Research raised Chemours from a “sell” rating to a “hold” rating in a report on Monday, March 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $46.00.

The company has a market capitalization of $4.15 billion, a price-to-earnings ratio of 4.19, a PEG ratio of 0.39 and a beta of 2.20. The company has a debt-to-equity ratio of 5.18, a current ratio of 1.81 and a quick ratio of 1.04.

Chemours (NYSE:CC) last released its quarterly earnings data on Thursday, May 2nd. The specialty chemicals company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.93 by ($0.30). The business had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.52 billion. Chemours had a return on equity of 87.75% and a net margin of 12.60%. The business’s revenue was down 20.5% on a year-over-year basis. During the same period last year, the company earned $1.41 EPS. As a group, equities analysts predict that Chemours Co will post 4.22 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Thursday, May 16th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.21%. The ex-dividend date is Wednesday, May 15th. Chemours’s dividend payout ratio (DPR) is 17.64%.

In other news, VP Amy Trojanowski sold 13,536 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $38.63, for a total value of $522,895.68. Following the completion of the transaction, the vice president now owns 54,367 shares of the company’s stock, valued at $2,100,197.21. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Mark Newman sold 59,210 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $38.26, for a total value of $2,265,374.60. Following the completion of the transaction, the vice president now directly owns 94,261 shares of the company’s stock, valued at approximately $3,606,425.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,924 shares of company stock valued at $3,924,730. Corporate insiders own 2.34% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Live Your Vision LLC lifted its position in shares of Chemours by 6.3% in the first quarter. Live Your Vision LLC now owns 4,993 shares of the specialty chemicals company’s stock worth $198,000 after buying an additional 295 shares in the last quarter. Financial Architects Inc lifted its position in shares of Chemours by 39.2% in the fourth quarter. Financial Architects Inc now owns 1,421 shares of the specialty chemicals company’s stock worth $40,000 after buying an additional 400 shares in the last quarter. Gulf International Bank UK Ltd lifted its position in shares of Chemours by 1.0% in the first quarter. Gulf International Bank UK Ltd now owns 40,350 shares of the specialty chemicals company’s stock worth $1,499,000 after buying an additional 400 shares in the last quarter. TCI Wealth Advisors Inc. lifted its position in shares of Chemours by 27.5% in the first quarter. TCI Wealth Advisors Inc. now owns 1,916 shares of the specialty chemicals company’s stock worth $71,000 after buying an additional 413 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Chemours by 2.2% in the first quarter. Crossmark Global Holdings Inc. now owns 23,040 shares of the specialty chemicals company’s stock worth $856,000 after buying an additional 500 shares in the last quarter. 82.18% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.wkrb13.com/2019/05/16/chemours-cc-stock-price-down-0-4.html.

About Chemours (NYSE:CC)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Article: Lock-Up Period Expiration

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.